Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Argus Research Upgrades Biogen to Buy

Argus Research Upgrades Biogen to Buy

Argus Research analyst Jasper Hellweg upgrades Biogen (NASDAQ:BIIB) from Hold to Buy.

byBenzinga Newsdesk

October 7, 2022

1 minute read

Argus Research analyst Jasper Hellweg upgrades Biogen (NASDAQ:BIIB) from Hold to Buy.

Barclays Downgrades Revolve Gr to Underweight, Lowers Price Target to $20

By Benzinga Newsdesk

August 15, 5:10 AM

Barclays analyst Ross Sandler downgrades Revolve Gr (NYSE:RVLV) from Equal-Weight to Underweight and lowers the price target from $30 to $20.

RVLV

Tellurian Q3 EPS $(0.03) Misses $0.02 Estimate, Sales $81.10M Miss $84.72M Estimate

By Benzinga Newsdesk

November 2, 7:30 AM

Tellurian (AMEX:TELL) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.02 by 250 percent. This is a 25 percent increase over losses of $(0.04) per share from the same

TELL

‘Potential Nightmare’: Ford, GM Thrust In Difficult Situation That Could Benefit Tesla, Says Analyst

By Bibhu Pattnaik

September 10, 10:06 AM

The potential strike by the United Auto Workers (UAW) union, which represents hourly workers at Detroit's big three automakers, could spell good news for Tesla Inc.

Top 3 Consumer Stocks That May Collapse In May

By Avi Kapoor

May 20, 8:25 AM

As of May 20, 2024, three stocks in the consumer discretionary sector could be flashing a real warning…

EAT

Argus Research Upgrades Biogen to Buy

Related Posts

Barclays Downgrades Revolve Gr to Underweight, Lowers Price Target to $20

Tellurian Q3 EPS $(0.03) Misses $0.02 Estimate, Sales $81.10M Miss $84.72M Estimate

‘Potential Nightmare’: Ford, GM Thrust In Difficult Situation That Could Benefit Tesla, Says Analyst

Top 3 Consumer Stocks That May Collapse In May